Australia | New Zealand | Total | ||||
---|---|---|---|---|---|---|
N | % | % | % | |||
Total evaluations | 318 | 66 | 384 | |||
Year published | ||||||
2010–2014 | 247 | 77.7% | 5 | 7.6% | 252 | 65.6% |
2015–2018 | 71 | 22.3% | 61 | 92.4% | 132 | 34.4% |
Base-year in model | ||||||
2000–04 | 207 | 65.1% | 0 | 0% | 207 | 53.9% |
2005–09 | 40 | 12.6% | 0 | 0% | 40 | 10.4% |
2010–15 | 71 | 22.3% | 66 | 100% | 137 | 35.7% |
Perspective | ||||||
Health sector/Health system | 143 | 45.0% | 64 | 97.0% | 207 | 53.9% |
Government | 4 | 1.3% | 0 | 0% | 4 | 1.0% |
Multiple (Health sector, Government, Patient, Societal) | 26 | 8.2% | 0 | 0% | 26 | 6.8% |
Societal (or limited societal) | 30 | 9.4% | 0 | 0% | 30 | 7.8% |
Not specified^ | 115 | 36.4% | 2 | 3.0% | 117 | 30.5% |
Time horizon | ||||||
10y to < lifetime | 13 | 4.1% | 0 | 0% | 13 | 3.4% |
Lifetime | 95 | 95.9% | 66 | 100% | 371 | 96.6% |
Discount rate (annual) | ||||||
3% | 318 | 100% | 66 | 100% | 384 | 100% |
Other | 0 | 0% | 0 | 0% | 0 | 0% |
Degree of targeting | ||||||
Population-wide | 112 | 35.2% | 48 | 72.7% | 160 | 41.7% |
Partially targeted | 180 | 56.6% | 14 | 21.2% | 194 | 50.5% |
Targeted | 26 | 8.2% | 4 | 6.1% | 30 | 7.8% |
Intervention duration | ||||||
One-off or up to 1 year | 64 | 20.1% | 16 | 24.2% | 80 | 20.8% |
1–5 years | 9 | 2.8% | 1 | 1.5% | 10 | 2.6% |
6–20 years | 20 | 6.3% | 1 | 1.5% | 21 | 5.5% |
Persistent | 172 | 54.3% | 48 | 72.7% | 220 | 57.3% |
Not specified | 53 | 16.7% | 0 | 0% | 53 | 13.8% |
Type of intervention | ||||||
Prevention | 298 | 93.7% | 57 | 86.4% | 355 | 92.4% |
Treatment | 20 | 6.3% | 4 | 6.1% | 24 | 6.3% |
Missing | 0 | 0% | 5 | 7.6% | 5 | 1.3% |
Type of comparator+ | ||||||
Current practice (Business-as-usual) | 137 | 43.1% | 30 | 45.5% | 167 | 43.5% |
Do nothing | 111 | 34.9% | 32 | 48.5% | 143 | 37.2% |
Other | 2 | 0.6% | 3 | 4.5% | 5 | 1.3% |
Not specified | 68 | 21.4% | 1 | 1.5% | 69 | 18.0% |
Domain | ||||||
Cancer | 27 | 8.5% | 8 | 12.1% | 35 | 9.1% |
Alcohol | 16 | 5.0% | 0 | 0% | 16 | 4.2% |
Cannabis or other illicit drugs | 5 | 1.6% | 0 | 0% | 5 | 1.6% |
Communicable disease | 7 | 2.2% | 5 | 7.6% | 12 | 3.1% |
Cardiovascular disease | 94 | 29.6% | 1 | 1.5% | 95 | 24.7% |
Diabetes | 13 | 4.1% | 0 | 0% | 13 | 3.4% |
Diet | 43 | 13.5% | 0 | 0% | 43 | 11.2% |
Injury | 1 | 0.3% | 5 | 7.6% | 6 | 1.6% |
Mental illness | 8 | 2.5% | 0 | 0% | 8 | 2.1% |
Other NCD | 26 | 8.2% | 0 | 0% | 26 | 6.8% |
Overweight & obesity | 45 | 14.2% | 1 | 1.5% | 46 | 12.0% |
Physical activity | 16 | 5.0% | 0 | 0% | 16 | 4.2% |
Salt (dietary) | 3 | 0.9% | 32 | 48.5% | 35 | 9.1% |
Tobacco | 14 | 4.4% | 14 | 21.2% | 28 | 7.3% |
Health gain | ||||||
HALYs per 1000 total population | ||||||
< 0.10 | 122 | 28.4% | 8 | 12.1% | 130 | 33.9% |
0.10–1 | 86 | 27.0% | 2 | 3.0% | 88 | 22.9% |
1–10 | 77 | 24.2% | 30 | 45.5% | 107 | 27.9% |
> 10 | 28 | 8.8% | 22 | 33.3% | 50 | 13.0% |
Missing† | 5 | 1.6% | 4 | 6.1% | 9 | 2.3% |
HALYs per person in target population | ||||||
< 01 | 28 | 8.8% | 23 | 34.9% | 51 | 13.3% |
01–099 | 0 | 0% | 20 | 30.3% | 20 | 5.2% |
0.1–0.99 | 1 | 0.3% | 3 | 4.5% | 4 | 1.0% |
Missing† | 289 | 90.9% | 20 | 30.3% | 309 | 80.5% |
Incremental health expenditure | ||||||
Net cost* per 1000 total population | ||||||
< US$0 [Cost saving] | 103 | 32.4% | 46 | 69.7% | 149 | 38.8% |
US$0 to $10,000 | 99 | 31.2% | 9 | 13.6% | 108 | 28.1% |
Cost > US$10,000 | 67 | 21.1% | 8 | 12.1% | 75 | 19.5% |
Missing† | 49 | 15.4% | 3 | 4.6% | 52 | 13.5% |
Net cost* per target population | ||||||
< US$0 [Cost saving] | 1 | 0.3% | 32 | 48.5% | 33 | 8.6% |
US$0 to $1000 | 24 | 7.6% | 10 | 15.2% | 34 | 8.9% |
Cost > US$1000 | 4 | 1.3% | 2 | 3.0% | 6 | 1.6% |
Missing† | 289 | 90.9% | 22 | 33.3% | 311 | 81.0% |
COST per HALY or Incremental cost-effectiveness ratio | ||||||
Cost saving | 97 | 30.5% | 47 | 71.2% | 144 | 37.5% |
US$0 to $50,000 per HALY | 127 | 39.9% | 17 | 25.8% | 144 | 37.5% |
> US$50,000 per HALY | 82 | 25.8% | 1 | 1.5% | 83 | 21.6% |
Dominated | 3 | 0.9% | 0 | 0% | 3 | 0.8% |
Missing† | 9 | 2.8% | 1 | 1.5% | 10 | 2.6% |